Future Health Care Equity ETF (GDOC)
| Assets | $21.45M |
| Expense Ratio | 0.75% |
| PE Ratio | 36.05 |
| Shares Out | 600,000 |
| Dividend (ttm) | $0.11 |
| Dividend Yield | 0.32% |
| Ex-Dividend Date | Dec 23, 2025 |
| Payout Frequency | n/a |
| Payout Ratio | 11.51% |
| Volume | 2,049 |
| Open | 35.66 |
| Previous Close | 35.63 |
| Day's Range | 35.49 - 35.66 |
| 52-Week Low | 28.34 |
| 52-Week High | 37.33 |
| Beta | 0.83 |
| Holdings | 40 |
| Inception Date | Nov 9, 2021 |
About GDOC
Fund Home PageThe Future Health Care Equity ETF (GDOC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed to provide exposure to equities of companies that are driving innovation in healthcare globally. GDOC was launched on Nov 9, 2021 and is issued by Goldman Sachs.
Top 10 Holdings
57.54% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 12.47% |
| Boston Scientific Corporation | BSX | 6.84% |
| Johnson & Johnson | JNJ | 6.35% |
| Thermo Fisher Scientific Inc. | TMO | 5.67% |
| AstraZeneca PLC | AZN | 5.66% |
| Intuitive Surgical, Inc. | ISRG | 5.06% |
| Abbott Laboratories | ABT | 4.68% |
| argenx SE | ARGX | 3.95% |
| Insulet Corporation | PODD | 3.46% |
| Guardant Health, Inc. | GH | 3.39% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2025 | $0.1133 | Dec 30, 2025 |
| Dec 23, 2024 | $0.00576 | Dec 30, 2024 |
| Dec 26, 2023 | $0.17894 | Jan 2, 2024 |
| Sep 26, 2022 | $0.00003 | Sep 30, 2022 |
Performance
GDOC had a total return of 10.49% in the past year, including dividends. Since the fund's inception, the average annual return has been -2.04%.
News
How Biotech ETF GDOC Is Sending a Red-Hot Buy Signal
Biotech investing may not be the most obvious place for investors to look right now, but factors may be turning in the category's favor. Multiple rate cuts in the back half of 2025 and a friendlier re...
Are Biotech ETFs Poised for a Surge? This Stock May Hold the Key
Is now the time to consider biotech ETFs? The stars may be aligning for investing in biotech as 2025 draws to a closer, with ETFs a key route into the space.
Goldman Sachs is building on the disruptive investing theme with a trio of new ETFs
Goldman Sachs Group is offering investors new ways to seek equity gains from disruptive companies, with its asset management business launching three exchange-traded funds focused on secular growth tr...